Impact of uterine artery embolization on ovarian function and pregnancy outcome after uterine-fibroids treatment: A prospective study

Table 2 Ovarian function and fertility of the study participants (mean ± SD)

Variable	UAE group (n = 87)	Control group (n = 87)	P value
FSH (IU/L)
Baseline	6.4 ± 1.2	6.5 ± 1.1	0.69
6 months	6.6 ± 1.3	6.7 ± 1.2	0.72
12 months	6.7 ± 1.4	6.8 ± 1.3	0.75
24 months	6.9 ± 1.5	7.0 ± 1.4	0.78
36 months	7.1 ± 1.6	7.2 ± 1.5	0.81
Change from baseline to 36 months	0.7 ± 0.8	0.7 ± 0.7	0.83
LH (IU/L)
Baseline	4.3 ± 1.1	4.4 ± 1.0	0.66
6 months	4.5 ± 1.2	4.6 ± 1.1	0.68
12 months	4.6 ± 1.3	4.7 ± 1.2	0.71
24 months	4.8 ± 1.4	4.9 ± 1.3	0.74
36 months	5.0 ± 1.5	5.1 ± 1.4	0.77
Change from baseline to 36 months	0.7 ± 0.9	0.7 ± 0.8	0.79
E2 (pg/mL)
Baseline	68.2 ± 15.4	69.3 ± 14.6	0.62
6 months	70.4 ± 16.2	71.5 ± 15.4	0.64
12 months	72.6 ± 17.0	73.7 ± 16.2	0.66
24 months	74.8 ± 17.8	75.9 ± 17.0	0.68
36 months	77.0 ± 18.6	78.1 ± 17.8	0.70
Change from baseline to 36 months	8.8 ± 10.2	8.8 ± 9.6	0.72
AMH (ng/mL)
Baseline	3.2 ± 1.4	3.3 ± 1.3	0.67
6 months	3.1 ± 1.3	3.2 ± 1.2	0.69
12 months	3.0 ± 1.2	3.1 ± 1.1	0.71
24 months	2.9 ± 1.1	3.0 ± 1.0	0.73
36 months	2.8 ± 1.0	2.9 ± 0.9	0.75
Change from baseline to 36 months	-0.4 ± 0.6	-0.4 ± 0.5	0.77
AFC
Baseline	12.4 ± 3.2	12.6 ± 3.1	0.65
6 months	12.2 ± 3.1	12.4 ± 3.0	0.67
12 months	12.0 ± 3.0	12.2 ± 2.9	0.69
24 months	11.8 ± 2.9	12.0 ± 2.8	0.71
36 months	11.6 ± 2.8	11.8 ± 2.7	0.73
Change from baseline to 36 months	-0.8 ± 1.2	-0.8 ± 1.1	0.75
OV (mL)
Baseline	8.6 ± 2.1	8.8 ± 2.0	0.63
6 months	8.4 ± 2.0	8.6 ± 1.9	0.65
12 months	8.2 ± 1.9	8.4 ± 1.8	0.67
24 months	8.0 ± 1.8	8.2 ± 1.7	0.69
36 months	7.8 ± 1.7	8.0 ± 1.6	0.71

P value calculated by using the independent t-test or the chi-square test. FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; E2: Estradiol; AMH: Anti-Müllerian hormone; AFC: Antral follicle count; OV: Ovarian volume; UAE: Uterine artery embolization.